Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

November 09, 2022

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.

November 04, 2022

Steven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.

November 04, 2022

Zachary Epstein-Peterson, MD, discusses the importance of treatment sequencing decisions in mantle cell lymphoma.

November 03, 2022

Rona Yaeger, MD, discusses the unmet needs for patients with KRAS G12C–mutated colorectal cancer and the promising combination therapy of adagrasib and cetuximab.

November 02, 2022

The FDA has approved cobimetinib (Cotellic) for the treatment of adult patients with histiocytic neoplasms.

October 28, 2022

The novel brain-penetrant ROS1-selective inhibitor NVL-520 elicited clinical activity and was well tolerated in heavily pretreated patients with ROS1 fusion–positive non–small cell lung cancer.

October 18, 2022

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

October 06, 2022

Single-agent neratinib produced robust responses in patients with metastatic or recurrent HER2-mutated cervical cancer, according to updated data from phase 2 SUMMIT basket trial.

October 03, 2022

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

September 21, 2022

Matthew J. Matasar, MD, discusses the unmet needs remaining in diffuse large B-cell lymphoma.

September 21, 2022

Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.

September 14, 2022

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

September 12, 2022

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.

September 11, 2022

Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.

September 11, 2022

The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.

September 11, 2022

A pan-tumor blood-based assay demonstrated a specificity of 99.1% and positive predictive value of 38.0% and resulted in a diagnosis of cancer in 35 individuals.

September 11, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

September 10, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

September 09, 2022

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

September 05, 2022

Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.